Complete their picture with a treatment that doesn’t settle for half
Somatuline® Depot doesn’t just treat half the problem. It is the only FDA-approved somatostatin analog (SSA) indicated to improve progression-free survival in GEP-NETs and proven to reduce the need for rescue medication in carcinoid syndrome in appropriate patients.1,2
INDICATIONS
Somatuline® Depot (lanreotide) is a somatostatin analog indicated for:1
the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs to improve progression-free survival; and
the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy
FDA=Food and Drug Administration; GEP-NET=gastroenteropancreatic neuroendocrine tumor;
PFS=progression-free survival; SSA=somatostatin analog.
Actor portrayal.
Complete their picture with a treatment that doesn’t settle for half
Somatuline® Depot doesn’t just treat half the problem. It is the only FDA-approved somatostatin analog (SSA) indicated to improve progression-free survival in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and proven to reduce the need for rescue medication in carcinoid syndrome in appropriate patients.1,2
INDICATIONS
Somatuline® Depot (lanreotide) is a somatostatin analog indicated for:1
the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP-NETs to improve progression-free survival; and
the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy
FDA=Food and Drug Administration; GEP-NET=gastroenteropancreatic neuroendocrine tumor;
PFS=progression-free survival; SSA=somatostatin analog.
Actor portrayal.
Caplin ME, Pavel M, Ćwikła JB, et al.; on behalf of the CLARINET Investigators. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371(3):224-233.
Vinik AI, Wolin EM, Liyanage N, et al.; on behalf of the ELECT Study Group. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22(9):1068-1080.
Wolin EM, Manon A, Chassaing C, et al. Lanreotide depot: an antineoplastic treatment of carcinoid or neuroendocrine tumors. J Gastrointest Cancer. 2016;47(4):366-374.
IMPORTANT SAFETY INFORMATION & INDICATIONS
Contraindications
SOMATULINE DEPOT is contraindicated in patients with hypersensitivity to lanreotide. Allergic reactions (including angioedema and anaphylaxis) have been reported following administration of lanreotide.
Warnings and Precautions
Cholelithiasis and Gallbladder Sludge
SOMATULINE DEPOT may reduce gallbladder motility and lead to gallstone formation.
Periodic monitoring may be needed.
If complications of cholelithiasis are suspected, discontinue SOMATULINE DEPOT and treat appropriately.
Hypoglycemia or Hyperglycemia
Patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.
Blood glucose levels should be monitored when SOMATULINE DEPOT treatment is initiated, or when the dose is altered, and antidiabetic treatment should be adjusted accordingly.
Cardiovascular Abnormalities
SOMATULINE DEPOT may decrease heart rate.
In patients without underlying cardiac disease, SOMATULINE DEPOT may lead to a decrease in heart rate without necessarily reaching the threshold of bradycardia.
In patients suffering from cardiac disorders prior to treatment, sinus bradycardia may occur. Care should be taken when initiating treatment in patients with bradycardia.
Most Common Adverse Reactions
GEP-NETs: Adverse reactions in >10% of patients who received SOMATULINE DEPOT were abdominal pain (34%), musculoskeletal pain (19%), vomiting (19%), headache (16%), injection site reaction (15%), hyperglycemia (14%), hypertension (14%), and cholelithiasis (14%).
Carcinoid Syndrome: Adverse reactions occurring in the carcinoid syndrome trial were generally similar to those in the GEP-NET trial. Adverse reactions in ≥5% of patients who received SOMATULINE DEPOT and at least 5% greater than placebo were headache (12%), dizziness (7%) and muscle spasm (5%).
Drug Interactions
SOMATULINE DEPOT may decrease the absorption of cyclosporine (dosage adjustment may be needed); increase the absorption of bromocriptine; and require dosage adjustment for bradycardia-inducing drugs (e.g., beta-blockers).
Special Populations
Lactation: Advise women not to breastfeed during treatment and for 6 months after the last dose.
SOMATULINE® DEPOT (lanreotide) is a somatostatin analog indicated for: the treatment of adult patients with unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival; and
the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy.
You are about to leave SomatulineDepot.com/hcp. This link is provided as a service to our website visitors. It will take you to another website maintained by Ipsen.
You are about to leave SomatulineDepot/hcp.com. This link is provided as a service to our website visitors. It will take you to a website maintained by a third party who is solely responsible for its content.
Ipsen does not control, recommend, endorse or accept liability for sites controlled by third parties.
You are about to leave SomatulineDepot.com/Hcp. This link is provided as a service to our website visitors. It will take you to another website maintained by Ipsen.
